Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis

被引:3
|
作者
Eaton, John E. [1 ]
Haseeb, Abdul [1 ]
Rupp, Christian [2 ]
Eusebi, Leonardo H. [3 ,4 ]
Munster, Kim [5 ]
Voitl, Robert [2 ]
Thorburn, Douglas [3 ,4 ]
Ponsioen, Cyriel Y. [5 ]
Enders, Felicity T. [6 ]
Petersen, Bret T. [1 ]
Abu Dayyeh, Barham K. [1 ]
Baron, Todd H. [1 ]
Chandrasekhara, Vinay [1 ]
Gostout, Christopher J. [1 ]
Levy, Michael J. [1 ]
Martin, John [1 ]
Storm, Andrew C. [1 ]
Dierkhising, Ross [6 ]
Kamath, Patrick S. [1 ]
Gores, Gregory J. [1 ]
Topazian, Mark [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55901 USA
[2] Univ Hosp Heidelberg, Dept Internal Med 4, Heidelberg, Germany
[3] Royal Free Hosp, Sheila Sherlock Liver Ctr, London, England
[4] UCL, Inst Liver & Digest Hlth, London, England
[5] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[6] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55901 USA
关键词
BILE-DUCT STRICTURES; DOMINANT STRICTURES; STENT THERAPY; EXPERIENCE; DILATION; STENOSES;
D O I
10.1002/hep4.1813
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The benefit of endoscopic retrograde cholangiopancreatography (ERCP) for the treatment of primary sclerosing cholangitis (PSC) remains controversial. To identify predictors of jaundice resolution after ERCP and whether resolution is associated with improved patient outcomes, we conducted a retrospective cohort study of 124 patients with jaundice and PSC. These patients underwent endoscopic biliary balloon dilation and/or stent placement at an American tertiary center, with validation in a separate cohort of 102 patients from European centers. Jaundice resolved after ERCP in 52% of patients. Median follow-up was 4.8 years. Independent predictors of jaundice resolution included older age (P = 0.048; odds ratio [OR], 1.03 for every 1-year increase), shorter duration of jaundice (P = 0.059; OR, 0.59 for every 1-year increase), lower Mayo Risk Score (MRS) (P = 0.025; OR, 0.58 for every 1-point increase), and extrahepatic location of the most advanced biliary stricture (P = 0.011; OR, 3.13). A logistic regression model predicted jaundice resolution with area under the receiver operator characteristic curve of 0.67 (95% confidence interval, 0.5-0.79) in the validation set. Independent predictors of death or transplant during follow-up included higher MRS at the time of ERCP (P < 0.0001; hazard ratio [HR], 2.33 for every 1-point increase), lower total serum bilirubin before ERCP (P = 0.031; HR, 0.91 for every 1 mg/dL increase), and persistence of jaundice after endoscopic therapy (P = 0.003; HR, 2.30). Conclusion: Resolution of jaundice after endoscopic treatment of biliary strictures is associated with longer transplant-free survival of patients with PSC. The likelihood of resolution is affected by demographic, hepatic, and biliary variables and can be predicted using noninvasive data. These findings may refine the use of ERCP in patients with jaundice with PSC.
引用
收藏
页码:809 / 820
页数:12
相关论文
共 50 条
  • [41] Predictive criteria of response to endoscopic treatment for severe strictures in primary sclerosing cholangitis
    Cazzagon, Nora
    Chazouilleres, Olivier
    Corpechot, Christophe
    El Mouhadi, Sanaa
    Chambenois, Edouard
    Desaint, Benoit
    Chaput, Ulriikka
    Lemoinne, Sara
    Arrive, Lionel
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2019, 43 (04) : 387 - 394
  • [42] Treatment options for primary sclerosing cholangitis
    Sinakos, Emmanouil
    Lindor, Keith
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (04) : 473 - 488
  • [43] Treatment of primary sclerosing cholangitis in children
    Trevor J Laborda
    M Kyle Jensen
    Marianne Kavan
    Mark Deneau
    World Journal of Hepatology, 2019, (01) : 19 - 36
  • [44] Current treatment of primary sclerosing cholangitis
    Wagner, S
    Meier, PN
    Maschek, H
    Nashan, B
    Manns, MP
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1998, 123 (11) : 325 - 327
  • [45] Tacrolimus for the treatment of primary sclerosing cholangitis
    Talwalkar, J
    GASTROENTEROLOGY, 2005, 128 (04) : A775 - A775
  • [46] Treatment options in primary sclerosing cholangitis
    Stiehl, A
    BIOLOGY OF BILE ACIDS IN HEALTH AND DISEASE, 2001, 120 : 326 - 330
  • [47] DIAGNOSIS AND TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS
    WIESNER, RH
    LUDWIG, J
    LARUSSO, NF
    MACCARTY, RL
    SEMINARS IN LIVER DISEASE, 1985, 5 (03) : 241 - 253
  • [48] Bezafibrate for the treatment of primary sclerosing cholangitis
    Suguru Mizuno
    Kenji Hirano
    Minoru Tada
    Keisuke Yamamoto
    Yoko Yashima
    Hiroshi Yagioka
    Kazumichi Kawakubo
    Yukiko Ito
    Hirofumi Kogure
    Takashi Sasaki
    Toshihiko Arizumi
    Osamu Togawa
    Saburo Matsubara
    Yousuke Nakai
    Naoki Sasahira
    Takeshi Tsujino
    Hiroyuki Isayama
    Takao Kawabe
    Masao Omata
    Kazuhiko Koike
    Journal of Gastroenterology, 2010, 45 : 758 - 762
  • [49] AZATHIOPRINE TREATMENT IN PRIMARY SCLEROSING CHOLANGITIS
    WAGNER, A
    LANCET, 1971, 2 (7725): : 663 - &
  • [50] Pirfenidone in the Treatment of Primary Sclerosing Cholangitis
    Paul Angulo
    Robert L. MacCarty
    Pamela B. Sylvestre
    Roberta A. Jorgensen
    Russell H. Wiesner
    Nicholas A. LaRusso
    Keith D. Lindor
    Digestive Diseases and Sciences, 2002, 47 : 157 - 161